The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | The impact of JAK2 allele burden and cytopenia on MF outcome in the era of ruxolitinib
Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a study investigating the impact of JAK2 allele burden and cytopenia on outcomes in myelofibrosis (MF). The study found that while JAK2 allele burden itself did not significantly affect outcomes, survival was notably longest in patients without cytopenia, whereas those with cytopenia and high white blood cell counts had poorer outcomes. Treatment with ruxolitinib showed beneficial effects across all patient groups, regardless of initial blood counts. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
